Vizgen is a biotech company that develops solutions for next-generation spatially resolved, single-cell transcriptomics.
Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The high throughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 3, 2022 | Series C | $85.20M | 7 |
ARCH Venture Partners
Blue Water Life Science Advisors
|
— | Detail |
| Apr 7, 2021 | Series B | $37M | 6 |
Novalis LifeSciences
|
— | Detail |
| Jan 30, 2020 | Series A | $14M | 2 |
ARCH Venture Partners
|
— | Detail |
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Dec 8, 2022
Metagood
|
Pre-seed | $5M | Cryptocurrency | — |
|
Jul 14, 2022
Trend
|
Pre-seed | $3M | Advertising Platforms | — |
|
Mar 4, 2022
Block Tackle
|
Seed | $5M | Blockchain | — |
|
Jan 11, 2022
Lootex
|
Seed | $9M | Blockchain | — |
|
Jan 5, 2022
CryptoSlam
|
Seed | $9M | Blockchain | — |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
Yes | Series C |
Blue Water Life Science Advisors
|
Yes | Series C |
|
|
— | Series C |
|
|
— | Series C |
Novalis LifeSciences
|
— | Series C |
Sofina
|
— | Series C |
Tao Capital Partners
|
— | Series C |
David R. Walt
|
— | Series B |
Pura Vida Investments
|
— | Series B |